The Cardiovascular Burden in End-Stage Renal Disease

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Chronic kidney disease (CKD) is strongly associated with increased cardiovascular disease (CVD) risk.
• Progressive decline in renal function correlates with a continuum of cardiovascular risk.
• End-stage renal disease (ESRD) patients exhibit a disproportionately high incidence of cardiac events.

Purpose of the Study:

• To explore the pathophysiological mechanisms linking CKD and CVD.
• To identify key biomarkers and conditions contributing to heightened cardiovascular risk in CKD patients.

Main Methods:

• Review of existing literature on CKD and CVD.
• Analysis of proposed pathophysiological pathways.
• Examination of relevant biomarkers and clinical conditions.

Main Results:

• CKD progression is a significant risk factor for CVD.
• Multiple factors contribute to CVD in CKD, including endothelial dysfunction, dyslipidemia, and inflammation.
• Biomarkers such as troponins, phosphate, vitamin D, fibroblast growth factor-23 (FGF-23), and NT-proBNP are associated with CVD in CKD patients.

Conclusions:

• CKD significantly elevates cardiovascular risk.
• Understanding the interplay between renal function decline and cardiovascular pathways is crucial.
• Associated biomarkers and conditions offer potential targets for risk mitigation in CKD patients.